GSK Receives US FDA Accelerated Approval for Nelkarmi in ALK-Positive Lung Cancer
GSK receives US FDA accelerated approval for Nelkarmi to treat adults with previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer.
Phase 1/2 ALKOVE-1 Trial | 19/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy